Edition:
United Kingdom

ProQR Therapeutics NV (PRQR.OQ)

PRQR.OQ on NASDAQ Stock Exchange Global Market

6.95USD
20 Jul 2018
Change (% chg)

-- (--)
Prev Close
$6.95
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
13,254
52-wk High
$7.45
52-wk Low
$2.78

Chart for

About

ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates... (more)

Overall

Beta: --
Market Cap(Mil.): $112.31
Shares Outstanding(Mil.): 24.11
Dividend: --
Yield (%): --

Financials

  PRQR.OQ Industry Sector
P/E (TTM): -- 85.33 32.76
EPS (TTM): -2.03 -- --
ROI: -68.51 2.22 14.61
ROE: -75.74 3.86 16.34

BRIEF-ProQR Announces Q1 Loss Per Share Eur 0.34

* AT MARCH 31, 2018, PROQR HELD CASH AND CASH EQUIVALENTS OF €38.0 MILLION, COMPARED TO €48.1 MILLION AT DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

09 May 2018

BRIEF-ProQR Provides Enrollment Update On QR-110 Clinical Trial

* PROQR PROVIDES ENROLLMENT UPDATE ON QR-110 CLINICAL TRIAL AND HIGHLIGHTS OPHTHALMOLOGY PRESENTATIONS AT ARVO

23 Apr 2018

BRIEF-Proqr Q4 Loss Per Share ‍Eur 0.39

* PROQR ANNOUNCES RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017 AND PROVIDES BUSINESS UPDATE

28 Feb 2018

Earnings vs. Estimates